department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

leronlimab · pharmadog

pharmadog
drugs
leronlimab

drug · antibody

patient view →

leronlimab

Phase 2updated 2mo ago

by $CYDY CytoDyn Inc.🔗 ChEMBL

Phase 2

community read0 votes

Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 7 investigational indications.

indications

indications

NSCLCMelanoma

targets

C-C chemokine receptor type 5

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

generic

leronlimab

MOA

C-C chemokine receptor type 5 antagonist

indication

Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH)

phase

phase_2

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 12m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying leronlimab

phase2The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)active not recruitingn=66
—An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)available
phase2Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumorscompletedn=16
phase2Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19completedn=484
phase2Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBCterminatedn=10
—A Compassionate Use Study of Leronlimab in Breast Cancerno longer available
phase2Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19completedn=56